KAMPALA – Dr. Matthias Magoola, the founder and Chief Executive Officer of Dei Group of Companies, has thanked President Museveni for standing up for Ugandan scientists in the face of several hurdles they face to innovate.
Dr. Magoola, who has been awarded a professional doctorate in management by the European International University of France, says President Museveni deserves praise for such achievements by a Ugandan scientist because, without his support, such milestones would not be possible.
“It is fair that we thank and credit him for these achievements,” Dr. Magoola said in tribute to President Museveni for supporting the Dei Biopharma drugs and vaccines manufacturing plant in Matugga, Wakiso district, near Kampala, the first biotech facility in Africa.
“These achievements are for Uganda and specifically for our dear President, for he has always stood up for the scientists in this country,” he added.
Dr. Magoola’s PhD award was announced by the University based in Paris, France, on February 19, 2024, at the 10th International Excellence and Global Leadership Award by Fame Times International Excellence Awards in Bangkok.
Dr. Magoola was recognized at the coronation ceremony as the leading entrepreneur of Africa, creating thousands of professional jobs. He is a published advanced therapeutics researcher and innovator and has established the largest pharmaceutical manufacturing and the first biotechnology products company in Uganda.
He has also pioneered manufacturing for mRNA, gene therapy, and other novel biological therapies, marking the first time these advancements are being developed in an African country.
A trained biochemist, Dr. Magoola has led the Dei Group over the years, developing a portfolio of sub-companies across diverse sectors. One of the most significant projects is the biological drugs and vaccines manufacturing facility in Matugga, Wakiso District, spearheaded by Dei Biopharma Ltd.
Dr. Magoola is recognized for his visionary success in innovative discoveries in advanced therapies, including:
- The first US-patented chemical drug using N-Isobutyll-3, 4-metheylenedioxy-trans-cinnamide compositions to treat malaria.
- The first mRNA universal vaccine against malaria.
- Other mRNA vaccines targeting neurodegenerative disorders, diabetes, HIV, and HPV.
- The mRNA-based vaccine composition for inducing an immune response against HIV and HPV, patented under certificate number 63921929 in the USA.
- Ten additional patents for treatments of previously untreatable diseases, all patented in the United States.
In the latest development, Dr. Magoola will lead a team of fellow scientists next month for a meeting with the US FDA to discuss their first product submission for innovation to treat cancers and severe anemia.
Additionally, Dr. Magoola has initiated technology transfer and facility finalization in Uganda, set to be completed within a few months.
Upon completion, the Matugga-based drugs and vaccines manufacturing plant, with a total cost of USD 1.1 billion, will produce a wide range of medicines and vaccines, including anti-cancer drugs and therapeutic proteins.
Beyond these innovations, Dr. Magoola’s contributions will create role models for other African scientists to lead research and development, instead of remaining at the receiving end of scientific advancements, as has been the historical norm for centuries.
SOURCE: PMLDAILY.COM
